---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-025335"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2026-05-27T12:00:25+00:00"
generated_at: "2026-05-27T12:06:03.484739+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MIRA secures worldwide rights for Ketamir-2, expands IP to 10 markets ahead of Phase 2a

## Summary
- Amendment expands licensed territory from US, Canada, Mexico to all countries with patent rights.
- IP portfolio now covers filings in 10 markets: US, Europe, China, Japan, Canada, Australia, India, Israel, Mexico, S. Korea.
- Core economic terms (royalties, financial consideration) of original license agreement unchanged.
- Company advancing Phase 2a protocol for FDA submission after positive Phase 1 data in 56 volunteers.

## SEC filing metadata
- accession: 0001493152-26-025335
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2026-05-27T12:00:25+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000149315226025335/0001493152-26-025335-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000149315226025335/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-025335
- JSON: https://secwatch.observer/filing/0001493152-26-025335.json
- Plain text: https://secwatch.observer/filing/0001493152-26-025335.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.